Beam Therapeutics Correlations
| BEAM Stock | USD 20.75 0.30 1.47% |
The current 90-days correlation between Beam Therapeutics and Editas Medicine is 0.62 (i.e., Poor diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Beam Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Beam Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Beam Therapeutics Correlation With Market
Weak diversification
The correlation between Beam Therapeutics and DJI is 0.35 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Beam Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Beam Stock
Moving against Beam Stock
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Beam Stock performing well and Beam Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Beam Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EDIT | 4.90 | 0.95 | 0.22 | 0.48 | 4.43 | 12.60 | 30.93 | |||
| CRSP | 2.85 | 0.66 | 0.22 | 0.56 | 2.83 | 7.09 | 16.14 | |||
| CRBU | 5.41 | 1.36 | 0.24 | 0.77 | 4.79 | 12.02 | 23.18 | |||
| VERV | 5.61 | 2.50 | 0.50 | (1.79) | 3.28 | 9.83 | 83.78 | |||
| NTLA | 4.15 | 0.93 | 0.12 | (1.82) | 5.53 | 8.60 | 36.46 | |||
| FATE | 5.24 | 0.29 | 0.06 | 0.29 | 5.90 | 12.61 | 39.69 | |||
| PRME | 6.84 | 1.82 | 0.30 | 1.04 | 5.67 | 21.58 | 41.91 | |||
| VRTX | 1.34 | (0.25) | 0.00 | (0.10) | 0.00 | 2.70 | 12.74 | |||
| DNA | 4.13 | 0.11 | 0.07 | 0.18 | 4.36 | 11.44 | 29.69 | |||
| SANA | 4.85 | 1.42 | 0.36 | 1.02 | 3.47 | 12.50 | 31.62 |
Beam Therapeutics Corporate Management
| Manmohan Singh | Chief Officer | Profile | |
| Nicole Gaudelli | CoFounder | Profile | |
| Brian Riley | VP Operations | Profile | |
| Susan OConnor | Chief Officer | Profile | |
| Alexis Komor | CoFounder | Profile | |
| Amy MD | Chief Officer | Profile | |
| Anne Woodland | Senior Affairs | Profile |